B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $15 from $14 and keeps a Buy rating on the shares following the Q3 report. The firm sees continued momentum across the company’s diversified business.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.